It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-08 21:38:39 Source:healthViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Britain's most notorious inmate Charles Bronson puts his parole bid in jeopardy after punch
Next:Vladimir Putin is sworn in for his fifth term as president at glittering ceremony in front of hand
You may also like
- World's largest deinonychosaur tracks discovered in Fujian
- Funding shortfall halts Taranaki Cathedral project
- Historic Tibetan Buddhist monastery is being moved to make way for dam — Radio Free Asia
- Tennessee fisherman reeled in a big one. It turned out to be an alligator
- Lizzo has all eyes on her in puzzling 'vase dress' with bowl
- Moon landing attempt: Another US lunar lander blasts off
- Two bodies found in search for Sydney couple Jesse Baird and Luke Davies
- In many African countries, abortions are legal. But information and access can be hard to come by
- China moves to tighten university lab safety management